Skip to content
The Nexus
HEALTHJul 23 · 10:45 UTCCNBC TOP

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Eli Lilly will file for approval of its next-generation obesity drug retatrutide in 2027 after achieving positive results in five late-stage trials. The drug is being positioned as a key component of the company's obesity portfolio.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Eli Lillyorganizationretatrutidetopicobesitytopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials · The Nexus